



NQF - Female Measures

E & M Codes: Clinic Only

Encounter Date(s): Jan 1, 2017 through Dec 31, 2017

| Location | Provider | Breast Cancer Screening | Cervical Cancer Screening | Chlamydia Screening | Osteoporosis Management in Women who had a Fracture |
|------------------------|------------------------|-------------------------|---------------------------|---------------------|---|
| SETMA 1 | Aziz | 44.7% | 46.8% | -- | 0.0% |
| | Duncan | 44.0% | 58.0% | 76.5% | 40.0% |
| | Halbert | -- | -- | -- | -- |
| | Henderson | 50.6% | 69.5% | 80.5% | 25.0% |
| | Holly | 54.8% | 50.9% | -- | 0.0% |
| | Le | 39.1% | 61.9% | 50.0% | 20.0% |
| | Murphy | 48.9% | 41.9% | 0.0% | 0.0% |
| | Palang | 49.8% | 62.8% | 33.3% | 10.0% |
| | Ramirez | 0.0% | 50.0% | -- | -- |
| | Smith | 100.0% | 0.0% | 0.0% | -- |
| | Thomas | 41.0% | 51.3% | -- | -- |
| SETMA 1 Totals: | | 46.8% | 59.8% | 72.7% | 17.7% |
| SETMA 2 | Akhter | 38.9% | 45.3% | -- | 0.0% |
| | Anthony | 40.9% | 47.2% | 50.0% | 12.5% |
| | Anwar | 48.2% | 41.6% | 0.0% | 0.0% |
| | Colbert | -- | -- | 50.0% | -- |
| | Darden | -- | 100.0% | -- | -- |
| | Kansara | 42.4% | 46.1% | 0.0% | 0.0% |
| | Smith | 45.7% | 54.0% | 45.5% | 12.5% |
| | Wheeler | 42.9% | 62.4% | 74.0% | 0.0% |
| | SETMA 2 Totals: | | 43.2% | 51.7% | 58.9% |
| SETMA Lumberton | Castro | 43.7% | 59.0% | 0.0% | 0.0% |
| | Colbert | -- | -- | 100.0% | -- |
| | Foster | 38.4% | 61.1% | 28.0% | 0.0% |
| | Halbert | 0.0% | 0.0% | -- | -- |
| | Holly | 41.2% | 53.3% | 100.0% | 0.0% |



NQF - Female Measures

E & M Codes: Clinic Only

Encounter Date(s): Jan 1, 2017 through Dec 31, 2017

| Location | Provider | Breast Cancer Screening | Cervical Cancer Screening | Chlamydia Screening | Osteoporosis Management in Women who had a Fracture |
|---------------------------------|--------------|-------------------------|---------------------------|---------------------|---|
| SETMA Lumberton | Horn | 30.0% | 22.2% | -- | -- |
| | Kansara | 27.8% | 37.0% | -- | -- |
| | Khan | 27.3% | 61.6% | 100.0% | -- |
| | Qureshi | 26.8% | 37.8% | 0.0% | -- |
| | Ramirez | 30.2% | 43.3% | 0.0% | 5.6% |
| SETMA Lumberton Totals: | | 34.5% | 52.2% | 25.6% | 3.8% |
| SETMA Mid County | Castro | 48.2% | 54.1% | 75.0% | 0.0% |
| | Feldschau | 40.4% | 33.3% | 16.7% | 33.3% |
| | George | 19.0% | 3.8% | -- | -- |
| | Le | 43.2% | 58.1% | 100.0% | -- |
| | Ramirez | 37.1% | 29.2% | -- | -- |
| | Shepherd | 34.4% | 19.4% | 0.0% | 20.0% |
| | Thomas | 24.2% | 13.5% | -- | 0.0% |
| SETMA Mid County Totals: | | 39.4% | 35.3% | 39.1% | 12.5% |
| SETMA Orange | Castro | 63.0% | 52.4% | -- | 0.0% |
| | Cox | 40.1% | 48.8% | 30.0% | 0.0% |
| | Green | 35.7% | 63.4% | 14.3% | -- |
| | Shepherd | 10.0% | 0.0% | -- | 0.0% |
| SETMA Orange Totals: | | 38.7% | 56.4% | 20.8% | 0.0% |
| SETMA West | Akhter | -- | 0.0% | -- | -- |
| | Darden | 33.2% | 52.7% | 73.7% | 0.0% |
| | Deiparine, C | 46.0% | 45.7% | 28.6% | 50.0% |
| | Halbert | 30.5% | 25.7% | 100.0% | 28.0% |
| | Horn | 44.8% | 50.1% | 83.3% | 5.6% |
| | Khan | 33.3% | 45.6% | 0.0% | 0.0% |
| | Qureshi | 35.8% | 46.3% | 45.5% | 0.0% |



NQF - Female Measures

E & M Codes: Clinic Only

Encounter Date(s): Jan 1, 2017 through Dec 31, 2017

| Location | Provider | Breast Cancer Screening | Cervical Cancer Screening | Chlamydia Screening | Osteoporosis Management in Women who had a Fracture |
|---------------------------|----------|-------------------------|---------------------------|---------------------|---|
| SETMA West Totals: | | 39.0% | 46.5% | 65.8% | 17.0% |
| SETMA Totals: | | 41.3% | 50.0% | 55.1% | 11.3% |

Breast Cancer Screening - Yearly mammography screening for women 40 to 69 years of age.

Cervical Cancer Screening - Cervical cancer screening for women 21 to 64 years of age at least every two years.

Chlamydia Screening - Sexually active females between the ages of 16 and 24 should have a Chlamydia screening at least yearly.

Osteoporosis Management In Women Who Had A Fracture - Women 67 years of age and older who suffered a fracture and who had either (1) a bone mineral density test or (2) a prescription for a drug to treat osteoporosis within six months following the fracture.